Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection

AIDS

Volumn 14, Issue 14, 2000, Pages 2145-2151

  Rutschmann, Olivier T ^a   Vernazza, Pietro L ^b   Bucher, Heiner C ^c   Opravil, Milos ^d   Ledergerber, Bruno ^d   Telenti, Amalio ^e   Malinverni, Raffaele ^f   Bernasconi, Enos ^g   Fagard, Catherine ^a   Leduc, Dominique ^a   Perrin, Luc ^a   Hirschel, Bernard ^a,h  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Canton Hospital St Gallen   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

^g Ospedale Civico Lugano   (Switzerland)

^h Faculty of Medicine   (Switzerland)

Author keywords

Didanosine; Highly active antiretroviral therapy; Hydroxyurea; Stavudine

Indexed keywords

DIDANOSINE; HYDROXYUREA; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FATIGUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; VIRUS LOAD; VOMITING;

ANTI-HIV AGENTS; DIARRHEA; DIDANOSINE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; HYDROXYUREA; NAUSEA; PERIPHERAL NERVOUS SYSTEM DISEASES; STAVUDINE;

EID: 0033791889     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200009290-00011     Document Type: Article

References (27)

1. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study
2. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance
3. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study
4. Long-term suppression of HIV-1 by hydroxyurea and didanosine
5. One-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection
6. The Swiss HIV Cohort Study : Rationale, organization and selected baseline characteristics
7. 3
8. The ALBI trial: A randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus
9. Once-daily administration of didanosine in combination with stavudine in antiretroviral-naive patients. The STADI Group
10. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine
11. Randomized trial of continued Indinavir(IDV)/ZDV/3TC vs switch to IDV/ddl/d4T or IDV/ddl/d4T + Hydroxyurea in patients with viral suppression
12. Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients
13. Hydroxyurea toxicity combined with didanosine (ddl) in HIV-1-seropositive asymptomatic individuals
14. Hydroxyurea toxicity in human immunodeficiency virus-positive patients
15. Structural changes in the megakaryocytes of patients infected with the human immune deficiency virus (HIV-1)
16. Neutropenia in patients infected with human immunodeficiency virus
17. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion
18. In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity
19. Effect of didanosine, stavudine, and hydroxyurea therapy on apoptosis in CD45RA+ and CD45RO+ T lymphocyte subpopulations
20. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine
21. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir)
22. Simultaneous vs sequential initiation of therapy with indinavlr, zidovudine, and lamivudine for HIV-1 infection - 100-Week follow-up
23. Longer time-to-treatment failure and durability of response with efavirenz + zdv + 3TC: First analysis of the full 1266 patient cohort from study 006
24. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
25. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
26. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group
27. Hydroxyurea-induced neurotoxicity in HIV disease